Claims
- 1. A pharmaceutical composition comprising a pharmacologically effective amount of a pharmacologically useful polypeptide and a pharmaceutically or veterinarily acceptable amphipathic, non-cross-linked linear, branched or graft block copolymer, which has a minimum weight average molecular weight of 5,000, in which the hydrophobic component is biodegradable or hydrolytically unstable under normal physiological conditions, and the hydrophilic component may or may not be biodegradable, the copolymer being capable of absorbing water to form a hydrogel when placed in water or an aqueous physiological-type environment in an animal body, the amphipathic copolymer being a linear block copolymer of the formula A.sub.m (BA).sub.n or B.sub.m (AB).sub.n wherein m is 0 or 1, n is an integer, A is a pharmaceutically or veterinarily acceptable hydrophobic polymer and B is a pharmaceutically or veterinarily acceptable hydrophilic polymer, or the amphipathic copolymer is a graft or branched block copolymer of the formula AB.sub.n or BA.sub.n wherein A, B and n have the meanings stated above and wherein respectively either A or B is a backbone polymer with n units of a monomer or polymer B or A respectively grafted onto it, and wherein A is selected from poly (D-, L- and DL-lactic acids), poly (D-, L- and DL-lactides), polyglycolic acid, polyglycolide, poly-.epsilon.-caprolactone, poly(3-hydroxy-butyric acid), non-therapeutic hydrophobic polypeptides, polyacetals of the formula ##STR4## wherein R is a hydrocarbon radical, and n has the meaning stated above, polycarbonates or polyorthoesters of the formula: ##STR5## wherein R and n have the meanings stated above, and copolymers of the formula: ##STR6## wherein R and n have the meanings stated above, and copolymers derived from two or more monomers from which the above polymers are derived; and the pharmaceutically or veterinarily acceptable hydrophilic polymer B is selected from polyvinyl alcohol, polyvinyl pyrrolidone, polyethylene glycol, polyacrylamide, polymethacrylamide, dextran, alginic acid, sodium alginate, and gelatine, and copolymers of two or more of the monomers from which the above polymers are derived, and polyoxyethylene/polyoxypropylene block copolymers.
- 2. A composition as claimed in claim 1 wherein A is a polymer of a lactide.
- 3. A composition as claimed in claim 2 wherein A is a polymer of a D,L-lactide and glycolide and B is polyethylene glycol.
- 4. A composition as claimed in claim 3 wherein the copolymer has the composition oxyethylene:lactic:glycol of 2:1:1.
- 5. A composition as claimed in claim 1 wherein the pharmacologically useful polypeptide is selected from the group consisting of oxytocin, vasopresin, adrenocorticotrophic hormone, epidermal growth factor, prolactin, luliberin or lutenising hormone releasing hormone, growth hormone, growth hormone releasing factor, insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, renin, bradykinin, bacitracins, polymyxins, colistins, tyrocidin, gramicidines, and synthetic analogues, modifications and pharmacologically active fragments thereof, monoclonal antibodies and soluble vaccines.
- 6. A composition as claimed in claim 1 wherein the polypeptide is Glu-His-Trp-Ser-Tyr-D-Ser(O-tBu)-Leu-Arg-Pro-Azgly-NH.sub.2.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8211704 |
Apr 1982 |
GBX |
|
Parent Case Info
This is a division of application Ser. No. 435,454, filed Apr. 15, 1983, now U.S. Pat. No. 4,526,938.
Non-Patent Literature Citations (1)
Entry |
Das, "Controlled Release Technology" John Wiley and Sons, Inc. 1983 pp. 9-10. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
485454 |
Apr 1983 |
|